ENTA on Nasdaq

ENANTA PHARMACEUTICALS INC

We are a biotechnology company that uses our robust, chemistry-driven approach and drug discovery capabilities to discover and develop small molecule drugs for virology and immunology indications.1

Price unavailable

Last updated Oct 19, 2026.

Overview

$65.3MRevenue, fiscal 20252
-$81.9MNet income, fiscal 20253

Compare with Lite Strategy, Inc., Zentalis Pharmaceuticals, Inc. or Fortress Biotech, or pick any stock.

  • TickerENTA on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersWatertown, Massachusetts1
  • Business address4 Kingsbury Avenue, Watertown, Ma 024724
  • Filer categoryNon-accelerated filer, Smaller reporting company4

See how the biggest companies compare on our leaderboards

We are a biotechnology company that uses our robust, chemistry-driven approach and drug discovery capabilities to discover and develop small molecule drugs for virology and immunology indications.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-130.7%Operating margin2
-125.4%Net margin3
-3.4%Revenue growth, 20252
-126.5%Return on equity2
-$32.2MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development98¢$106.7M
  • Income tax2¢$1.7M

Out of $65.3M in revenue.23 The company lost money this year.

Financial statements

Revenue6789102$65.3M in 2025−68% since 2018
0$100.0M$200.0M$300.0M2018: $206.6M$206.6M20182019: $205.2M$205.2M2019−1%2020: $122.5M$122.5M2020−40%2021: $97.1M$97.1M2021−21%2022: $86.2M$86.2M2022−11%2023: $79.2M$79.2M2023−8%2024: $67.6M$67.6M2024−15%2025: $65.3M$65.3M2025−3%
Operating income6789102-$85.3M in 2025
-$200.0M-$100.0M0$100.0M2018: $88.3M$88.3M20182019: $36.7M$36.7M2019−58%2020: -$41.6M-$41.6M20202021: -$109.6M-$109.6M2021+163%2022: -$123.8M-$123.8M2022+13%2023: -$137.2M-$137.2M2023+11%2024: -$121.7M-$121.7M2024−11%2025: -$85.3M-$85.3M2025−30%
Net income67891023-$81.9M in 2025
-$200.0M-$100.0M0$100.0M2018: $72.0M$72.0M20182019: $46.4M$46.4M2019−36%2020: -$36.2M-$36.2M20202021: -$79.0M-$79.0M2021+118%2022: -$121.8M-$121.8M2022+54%2023: -$133.8M-$133.8M2023+10%2024: -$116.0M-$116.0M2024−13%2025: -$81.9M-$81.9M2025−29%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-09-302024-09-302023-09-30
Total revenue$65.3M$67.6M$79.2M
Research and development$106.7M$131.5M$163.5M
General and administrative$43.9M$57.9M$52.9M
Total operating expenses$150.7M$189.3M$216.4M
Loss from operations-$85.3M-$121.7M-$137.2M
Interest expense-$7.7M-$10.9M-$5.1M
Interest and investment income, net$9.4M$14.8M$11.4M
Change in fair value of Series 1 nonconvertible preferred stock$39.0K$73.0K$0
Total other income, net$1.8M$3.9M$6.2M
Loss before income taxes-$83.5M-$117.8M-$131.0M
Income tax benefit (expense)$1.7M$1.7M-$2.8M
Net loss-$81.9M-$116.0M-$133.8M
Basic-$3.84-$5.48-$6.38
Diluted-$3.84-$5.48-$6.38
Basic21.3K shares21.2K shares21.0K shares
Diluted21.3K shares21.2K shares21.0K shares

Compare ENANTA PHARMACEUTICALS INC with another company

Leadership

Who has led ENANTA PHARMACEUTICALS INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jay R. Luly2013–now

President

  1. Jay R. Luly2013–now

Chief financial officer

  1. Paul J. Mellett2013–2023
201520202025
Board members and other officers (26)

Timeline

  1. Mar 20, 2013New chief executive Jay R. Luly becomes CEO13

Filings

321 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 43 major events, 179 insider forms, 39 large holders, 40 other. The latest 20:

  1. Aug 14, 2026SCHEDULE 13G/A EDGAR
  2. Aug 14, 2026SCHEDULE 13G/A EDGAR
  3. Aug 12, 202610-Q EDGAR
  4. Aug 10, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  5. Aug 10, 20268-K EDGAR
  6. Jul 2, 20268-K EDGAR
  7. Jul 2, 2026424B5 EDGAR
  8. Jun 23, 20268-K EDGAR
  9. Jun 18, 20268-K EDGAR
  10. May 13, 2026S-8 EDGAR
  11. May 13, 202610-Q EDGAR
  12. May 11, 20268-K EDGAR
  13. Mar 26, 20268-K EDGAR
  14. Mar 26, 2026SCHEDULE 13G/A EDGAR
  15. Mar 13, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  16. Mar 13, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  17. Mar 13, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  18. Mar 13, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  19. Mar 13, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  20. Mar 13, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR

The 321 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

43 open-market trades by officers, directors and large owners since October 2021: 1 buys and 42 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 5, 2025Capps Kathleen S.See RemarksSale323$14.23$4.6KForm 4
Dec 5, 2025Trout Harry R. IIISee RemarksSale542$14.23$7.7KForm 4
Dec 5, 2025Rottinghaus Scott T.Chief Medical OfficerSale798$14.23$11.4KForm 4
Dec 5, 2025Luu BrendanChief Business OfficerSale1,394$14.23$19.8KForm 4
Dec 5, 2025Kieffer Tara LynnChief Product Strategy OfficerSale2,106$14.23$30.0KForm 4
Dec 5, 2025Or Yat SunChief Scientific OfficerSale2,390$14.23$34.0KForm 4
Dec 5, 2025Luly Jay R.President and CEOSale4,743$14.23$67.5KForm 4
Dec 2, 2025Capps Kathleen S.See RemarksSale207$13.96$2.9KForm 4
Dec 2, 2025Trout Harry R. IIISee RemarksSale380$13.96$5.3KForm 4
Feb 12, 2025Luly Jay R.President and CEOBuy45,000$5.69$256.1KForm 4
Dec 6, 2024Kieffer Tara LynnChief Product Strategy OfficerSale2,283$8.06$18.4KForm 4
Dec 6, 2024Luu BrendanChief Business OfficerSale2,283$8.06$18.4KForm 4
Dec 6, 2024Rottinghaus Scott T.Chief Medical OfficerSale866$8.06$7.0KForm 4
Dec 6, 2024Or Yat SunChief Scientific OfficerSale2,591$8.06$20.9KForm 4
Dec 6, 2024MELLETT PAUL JChief Fin. & Admin OfficerSale2,591$8.06$20.9KForm 4
Dec 6, 2024Luly Jay R.President and CEOSale5,142$8.06$41.4KForm 4
Jul 15, 2024Rottinghaus Scott T.Chief Medical OfficerSale5,375$17.08$91.8KForm 4
Jul 12, 2024Rottinghaus Scott T.Chief Medical OfficerSale2,271$15.04$34.2KForm 4
Jul 11, 2024Rottinghaus Scott T.Chief Medical OfficerSale4,299$15.07$64.8KForm 4
Jun 17, 2024Kieffer Tara LynnChief Product Strategy OfficerSale7,266$12.33$89.6KForm 4

All 43 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Jupiter Topco LLC3,654,920$53.3M0.0%New
BlackRock, Inc.3,244,448$47.3M0.0%+140,680
Farallon Capital Management, L.l.c.2,418,202$35.3M0.2%−453,660
Deep Track Capital, LP1,444,167$21.1M0.3%−512,700
ADAR1 Capital Management, LLC1,344,510$19.6M0.9%+1,293,153
Vanguard Capital Management LLC1,211,769$17.7M0.0%+33,720
Spruce Street Capital LP1,088,731$15.9M3.1%+156,133
Vanguard Portfolio Management LLC1,011,494$14.7M0.0%+62,590
Geode Capital Management, LLC776,634$11.3M0.0%+51,573
Millennium Management LLC643,967$9.4M0.0%−238,130
State Street Corp576,117$8.4M0.0%+14,011
Renaissance Technologies LLC557,600$8.1M0.0%−107,658
Hillsdale Investment Management Inc.468,000$6.8M0.2%+32,490
Goldman Sachs Group Inc464,649$6.8M0.0%+199,561
Morgan Stanley315,729$4.6M0.0%+6,218
Charles Schwab Investment Management Inc301,151$4.4M0.0%+6,180
Dimensional Fund Advisors LP282,682$4.1M0.0%+79,430
Northern Trust Corp259,696$3.8M0.0%+18,728
SummitTX Capital, L.P.257,702$3.8M0.1%New
Aqr Capital Management LLC256,870$3.7M0.0%−56,287
Vanguard Fiduciary Trust Co185,618$2.7M0.0%+9,762
Connor, Clark & Lunn Investment Management Ltd.153,008$2.2M0.0%+27,249
Rockefeller Capital Management L.P.150,546$2.2M0.0%+147,983
Marshall Wace, Llp131,995$1.9M0.0%−78,075
Opaleye Management Inc.125,000$1.8M0.2%No change

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Jul 12, 2023Daniel S. GoldmanDemocratic, HouseSale$1,001 - $15,000+116.3%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53